Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

aTYR PHARMA (ATYR) Income from Non-Controlling Interests (2020 - 2025)

aTYR PHARMA (ATYR) has disclosed Income from Non-Controlling Interests for 6 consecutive years, with -$1000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Income from Non-Controlling Interests changed 0.0% year-over-year to -$1000.0, compared with a TTM value of -$5000.0 through Dec 2025, down 600.0%, and an annual FY2025 reading of -$5000.0, down 600.0% over the prior year.
  • Income from Non-Controlling Interests was -$1000.0 for Q4 2025 at aTYR PHARMA, up from -$2000.0 in the prior quarter.
  • Across five years, Income from Non-Controlling Interests topped out at $4000.0 in Q1 2024 and bottomed at -$4000.0 in Q1 2021.
  • Average Income from Non-Controlling Interests over 5 years is -$1368.4, with a median of -$1000.0 recorded in 2021.
  • The sharpest move saw Income from Non-Controlling Interests crashed 300.0% in 2023, then skyrocketed 500.0% in 2024.
  • Year by year, Income from Non-Controlling Interests stood at -$2000.0 in 2021, then changed by 0.0% to -$2000.0 in 2022, then soared by 50.0% to -$1000.0 in 2023, then changed by 0.0% to -$1000.0 in 2024, then changed by 0.0% to -$1000.0 in 2025.
  • Business Quant data shows Income from Non-Controlling Interests for ATYR at -$1000.0 in Q4 2025, -$2000.0 in Q3 2025, and -$1000.0 in Q2 2025.